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Abstract
Background: The capacity of the AMS scale as clinical utility and as outcome measure still needs
validation.
Methods: An open post-marketing study was performed by office-based physicians in Germany in
2004. We analysed data of 1670 androgen-deficient males who were treated with testosterone gel.
The AMS scale was applied prior to and after 3 months treatment.
Results: The improvement of complaints under treatment relative to the baseline score was 30.7%
(total score), 27.3% (psychological domain), 30.5% (somatic domain), and 30.7% (sexual domain),
respectively. Patients with little or no symptoms before therapy improved by 9%, those with mild
complaints at entry by 24%, with moderate by 32%, and with severe symptoms by 39% – compared
with the baseline score. We showed that the distribution of complaints of testosterone deficient
men before therapy almost returned to norm values after 12 weeks of testosterone treatment.
Age, BMI, and total testosterone level at baseline did not modify the positive effect of androgen
therapy. We also demonstrated that the AMS results can predict the independent (physician's)
opinion about the individual treatment effect. Both, sensitivity (correct prediction of a positive
assessment by the physician) and specificity (correct prediction of a negative assessment by the
physician) were over 70%, if about 22% improvement of the AMS total score was used as cut-off
point.
Conclusion: The AMS scale showed a convincing ability to measure treatment effects on quality
of life across the full range of severity of complaints. Effect modification by other variables at
baseline was not observed. In addition, results of the scale can predict the subjective clinical expert
opinion on the treatment efficiency.
Background
The Aging Males' Symptoms (AMS) scale was originally
developed in Germany as a health-related quality of life
scale (HRQoL) [1]. The scale was designed as self-admin-
istered scale (a) to assess symptoms of aging (independ-
ent from those which are disease-related) between groups
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of males under different conditions, (b) to evaluate the
severity of symptoms over time, and (c) to measure
changes pre- and post androgen therapy [1]. It was devel-
oped in response to the lack of fully standardized scales to
measure the severity of aging symptoms and their impact
on HRQoL in males, specifically [2,3]. It was recently
demonstrated by a French research group that the AMS
scale measures HRQoL similarly in younger (even 20–30
years old) and older persons [4]. Right from the beginning
a possible screening potential of the AMS scale was con-
troversially discussed. Therefore we compared the AMS
scale with internationally well-known screening instru-
ments for androgen deficiency in adult males (ADAM
scale of Morley et al [5] and the Screener of Smith' et al [6].
We found that the AMS has obviously similar test charac-
teristics as both screening instruments [7]. Later, the sim-
ilarity of AMS and ADAM was confirmed in another study
[8]. In addition, Kratzik et al [9] observed in a population-
based cross-sectional study in Vienna an impressive asso-
ciation between subscales of the AMS and free testoster-
one level when age and body mass index was
multivariately taken into account. Recently, a Japanese
research group under Itoh et al [10] and Soh et al [11]
observed a correlation between the AMS scores and the
testosterone level. A Polish research group found a similar
but less clear result [12]. Other studies, however, could
not find associations of the AMS scores with testosterone
level [13,14].
Meanwhile, the AMS scale was internationally well
accepted: it is now available in 21 languages [2,15,16],
and can be down loaded from the internet http://
www.aging-males-symptom-scale.info.
The evaluation of the AMS scale is simple; the scheme has
been published [4]. Norm values to compare with were
determined [1,3]. Conventional psychometric require-
ments of test reliability and validity have been successfully
achieved and published [17,18]. A point was reached to
demonstrate the capacity of the scale to reliably measure
the effect of androgen treatment or to predict the magni-
tude of the therapeutic effect subjectively perceived by the
treating physician. To this end, many clinicians use the
term "validity" and mean high utility for clinical work or
research.
It was shown in a previous publication that the AMS scale
meets the requirements of a clinical utility and outcomes
sensitivity [7]. The focus of this paper however is to ana-
lyze if variables such as age, body mass index (BMI), sever-
ity of complaints, and testosterone level before treatment
effect the outcome measured with the AMS scale.
Methods
An open post-marketing study was conducted together
with office-based physicians in Germany in 2004. The
study monitored the effect of androgen substitution on
complaints as well as adverse reactions of a licensed testo-
sterone gel product (Testogel JENAPHARM®) under rou-
tine conditions. The eligibility of male patients for
androgen therapy was determined by the prescribing phy-
sician, i.e. following the recommendations of the Interna-
tional Society for The Study of the Aging Male (ISSAM)
[19] for testosterone treatment in patients with androgen
deficiency. No other inclusion or exclusion criteria were
set up except the consent between the patient and his
treating doctor. The needed sample size was not deter-
mined for this observational three months follow-up
study.
The observation encompassed three visits which were
documented in a short form: before treatment, after 4–6
weeks, and at the end of the observation period of 12
weeks. A short questionnaire was completed by the treat-
ing physician to characterize the patient at baseline, after
4–6 weeks androgen treatment, and at the end of the
study (3 months). The physician subjectively assessed the
treatment effect at each of the three visits, and listed also
adverse reactions on a specific form.
We got for this methodological paper a database with the
AMS scale completed before therapy and after 12 weeks,
age, BMI and total testosterone (TT). However, only a sub-
sample had TT values available.
The computerized data of this post-marketing study were
analyzed with conventional statistics using the statistical
package SAS 9.1®.
Table 1: Baseline parameters of the study participants
na Mean (S.D)
Age (years) 1670 56.4 (10.8)
Body mass index (kg/m2) 1670 26.8 (3.1)
Testosterone-level at baseline (ng/ml) 1670 2.5 (1.1)
nb %
Smoker: Yes, current smoker 1661 32.1
Alcohol (yes: often/regularly) 1660 11.9
Diabetes mellitus (yes) 1542 16.9
Hypertension (yes) 1578 34.2
Cardiovascular conditions (yes) 1533 12.0
Chronic pulmonary conditions (yes) 1504 8.1
Tumour (yes) 1527 9.0
na number of men who had no missings in certain variables which 
were used as independent variables for analysis; nb proportion of the 
total of 1670 men who provided information on a certain parameter.Health and Quality of Life Outcomes 2006, 4:23 http://www.hqlo.com/content/4/1/23
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Results and discussion
Altogether, 1670 patients were available for analysis. A
general description of the group analyzed in this paper is
given in Table 1. The mean age was of 56.4 years, the
mean BMI was 26.8, and the TT at baseline was 2.5 ng/ml.
A great proportion of the participants had a medical his-
tory of one or more chronic diseases. In addition, alcohol
consumption and smoking were quite frequent (see table
1).
The HRQoL improved after 12 weeks of testosterone-gel
application as measured with the total score of the AMS
scale. Relative to the scores at baseline, the total score, the
scores for the psychological, somato-vegetative, and sex-
ual scores improved 30.7%, 27.3%, 30.5%, and 30.7%
compared with the baseline score, respectively. This is an
almost identical relative improvement of the HRQoL as
shown in an earlier study associated with injectable testo-
sterone [7].
The higher severity of complaints at baseline the greater is
the improvement as demonstrated for the AMS total score
in Figure 1. This applies also for the three sub-scales (data
not shown). This was expected but an important observa-
tion with impact on the methodological assessment
(validity) of the AMS scale.
Compared with the distribution of complaints in the nor-
mal population (=norm values [1,3]), the markedly
altered HRQoL in this androgen deficient males shifted
towards the "norm" of the male population over 40 years
after androgen treatment (Figure 2). Patients under 40
were excluded for this comparison (n = 137). It seems to
be important to underscore: There was a positive effect
Improvement of complaints under androgen therapy Figure 1
Improvement of complaints under androgen therapy. Difference between pre- and post-treatment AMS total score divided by 
pre-treatment score in percent (%). Stratification by four categories of severity of complaints at baseline.
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Improvement of complaints (%) compared with total score at baseline
9.2 + 13.2
39.2 + 15.3
23.8 + 15.6
31.5 + 14.3
No/little complaints
Mild symptoms
Moderate symptoms
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(taken numbers at face value) detectable even in males
with mild or even little symptoms. Almost identical obser-
vations concerning improvement of complaints after
androgen therapy were made for injectable testosterone in
a previous study [17]. Thus, two independent observa-
tional studies (with the same methodology) found the
same pattern, but there is still a need for confirmation in
a randomised clinical trial.
To answer the question if the treatment-related improve-
ment depends on age, BMI, and testosterone level at base-
line, we run a stratified analysis (one-way analysis of
variance). Table 2 shows the relative improvement after
therapy for the AMS total score, and also for the three sub-
scores. There is neither much difference in relative
improvement among age, BMI or testosterone groups nor
among subscales. All significant changes of HRQoL range
around 30% improvement compared with baseline
(before therapy). There is no clinically consistent and rel-
evant impact on the magnitude of improvement of the
three variables at baseline (age, BMI, TT) considering the
size of the standard deviation (in brackets), although the
Tuckey-Test showed a few significant effects of age and
BMI but with contradictory direction of the trend of the
effect, i.e. random findings due to multiple testing cannot
be excluded. It cannot be excluded either that the study
group is too homogeneous to find small effects.
Another question was to what extend the evaluation with
the AMS scale could "predict" the opinion of the treating
physician regarding "success" of the androgen therapy.
The treating physician subjectively assessed the "success"
without knowing the results of the AMS he had no access
to. Sensitivity (correct prediction of a positive assessment
Relative frequency distribution in four categories of severity of complaints measured with AMS (total score): in the normal  male population [1, 3] (left side), in patients with AD before and after therapy (middle and right columns) Figure 2
Relative frequency distribution in four categories of severity of complaints measured with AMS (total score): in the normal 
male population [1, 3] (left side), in patients with AD before and after therapy (middle and right columns).
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by the physician) and specificity (correct prediction of a
negative assessment by the physician) are important char-
acteristics for a test that intends to "diagnose" successful
therapy – like AMS in this case (predictive validity).
As can be seen in Table 3, we plotted the sensitivity and
specificity in a kind of ROC analysis against the degree of
improvement of complaints found under androgen treat-
ment (difference between the pre- and post-treatment
score on AMS as percent of pre- treatment total score).
More than 22% relative improvement of the total AMS
score seems a suitable cut-off point for "diagnosing treat-
ment success": both sensitivity and specificity were about
70% and thereby acceptably high. In other words, the
AMS scale is able to assess the treatment success with suf-
ficient good test characteristics, validated against the
expert opinion of the treating physician. It could be an
advantage of a "success diagnosis" with the AMS scale
because it is directly based on patients' view, whereas the
physician's assessment could be rather a varying mixture
of theoretical expectation/experience and patient's report.
Anyway, since the methodological characteristics of the
AMS scale are pretty good it is worthwhile to get experi-
ence with this tool in clinical practice. It might be recom-
mendable to apply a standardized "objective" scale like
the AMS scale in clinical studies, and in addition – if nec-
essary – the subjective, not standardizable judgment of a
physician.
It seems important to underline that this paper has a suf-
ficient basis to describe the validity of the scale, but there
is no intention to discuss the efficacy of testosterone sub-
stitution. This would be the task of a double-blinded, pla-
cebo controlled trial. We could just demonstrate that the
AMS as measure of health-related quality of life (HRQoL)
is able to detect changes in quality of life following andro-
gen substitution in androgen-deficient males – irrespec-
tive of the specific drug used as treatment or the specific
underlying diagnosis in this observational follow up
study. This confirms results of an earlier post-marketing
study [7] that showed acceptably good validity.
The AMS scale can be applied in clinical trials both in
young hypogonadel men as well as in late-onset hypogo-
nadism according to French experience [4]: The scale
measures the same phenomenon in different age groups,
and no obvious differences exist in reference values. We
recommend the use of the total score as outcome meas-
ure, but domain scores can be used as well. From our cur-
rent experience we would conclude that the same cut-off
point should be used as "treatment success" when plan-
Table 3: Sensitivity and specificity of potential cut-off points for 
the "diagnosis of treatment success" using the relative 
improvement of AMS total score (ROC-Analysis)
Cut-off Point relative score 
improvement
Sensitivity (%) Specificity (%)
≥5 % 93.5 24.0
≥10 % 90.7 32.8
≥15 % 84.9 49.6
≥20 % 76.3 64.8
≥22 % 73.6 70.4
≥25 % 67.2 78.4
≥30 % 56.3 87.2
≥35 % 43.9 92.8
≥40 % 31.1 93.6
Table 2: Improvement of AMS scores after testosterone-gel therapy. Stratification by age, BMI, and testosterone categories at 
baseline. The relative improvement is the difference between the pre- and post-treatment score divided by pre-treatment score as 
percents (%). Wilcoxon signed rank test was used to test differences of significance
Total score Psychological score Somatic score Sexual score
n%p%P%p%p
All 1670 30.7 (17.3) < .0001 27.3 (22.4) < .0001 30.5 (18.7) < .0001 30.7 (20.6) < .0001
Age
< 50 380 28.0 (18.4) < .0001 23.8 (22.6) < .0001 27.4 (20.0) < .0001 28.3 (23.1) < .0001
50–59 577 33.2 (17.6) < .0001 29.4 (22.9) < .0001 32.3 (19.2) < .0001 34.4 (20.0) < .0001
60+ 713 30.1 (16.3) < .0001 27.5 (21.6) < .0001 30.6 (17.3) < .0001 29.0 (19.1) < .0001
BMI (kg/m2
< 24.8 408 28.9 (17.5) < .0001 25.0 (22.5) < .0001 28.7 (18.4) < .0001 28.8 (21.5) < .0001
24.8 – 
28.3
849 32.6 (16.3) < .0001 29.4 (21.6) < .0001 32.0 (18.1) < .0001 33.1 (18.7) < .0001
28.4+ 413 28.4 (18.7) < .0001 25.2 (23.5) < .0001 28.9 (19.9) < .0001 27.5 (22.6) < .0001
Total 
testosteron
e (ng/ml)
< 1.81 424 31.0 (17.8) < .0001 27.2 (22.5) < .0001 31.1 (19.8) < .0001 30.3 (21.8) < .0001
1.81 – 
2.99
832 31.3 (16.3) < .0001 28.0 (21.8) < .0001 30.8 (18.0) < .0001 31.6 (18.8) < .0001
3.00+ 414 29.1 (18.6) < .0001 26.1 (23.4) < .0001 29.1 (18.9) < .0001 28.2 (23.4) < .0001Publish with BioMed Central    and   every 
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ning a trial. However, we had no access to data from ran-
domized clinical trials to really investigate this issue.
Conclusion
The AMS scale showed a convincing ability to measure
treatment effects on quality of life across the full range of
severity of complaints. Effect modification by other varia-
bles at baseline (age, BMI, and testosterone level) on the
"treatment associated effect on AMS score" was not
observed. In addition, results of the scale can predict the
subjective clinical expert opinion on the treatment effi-
ciency.
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